Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 173 clinical trials
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation

  • 0 views
  • 12 May, 2022
  • 2 locations
  • 0 views
  • 08 Jul, 2021
  • 1 location
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

The purpose of this study is to evaluate the safety and efficacy of dabrafenib in combination with trametinib in Chinese patients with BRAF V600E mutation-positive metastatic Non-Small Cell Lung

neutrophil count
lung carcinoma
secondary malignant neoplasm of liver
measurable disease
BRAF
  • 7 views
  • 04 Jul, 2022
  • 1 location
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab

  • 0 views
  • 19 Oct, 2021
  • 1 location
  • 0 views
  • 05 Jul, 2021
  • 1 location
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

mCRC patients, whose tumors remain RAS/BRAF WT. The study will also evaluate the activity and efficacy of cetuximab re-introduction in combination with irinotecan as third line therapy in the concept

  • 0 views
  • 27 Apr, 2022
  • 8 locations
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)

This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with

  • 0 views
  • 28 Jul, 2022
  • 4 locations
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved

neutrophil count
spiral computed tomography
ct scan
KRAS
measurable disease
  • 1 views
  • 09 Jul, 2022
  • 2 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 07 Feb, 2022
  • 13 locations
CRAFT: The NCT-PMO-1602 Phase II Trial

revealed genetic alterations in a substantial proportion of patients including (i) alterations that lead to aberrant activation of BRAF, ERBB2, ALK, and the PI3K-AKT and MAPK pathways and (ii) changes that

  • 0 views
  • 15 Jun, 2022
  • 4 locations